While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...

GenAssist’s IND application for GEN6050X receives US FDA clearance, a globally first-in-class base editing drug for duchenne muscular dystrophy: Suzhou, China Friday, March 7, 2 ...

PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

The Duchenne muscular dystrophy (DMD ... In line with this, exon-skipping therapies dominate the therapeutic landscape, generating approximately $1b in sales in the 7MM in 2023.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

ENTR-601-44, an investigational therapy for the potential treatment of people living with Duchenne who are exon 44 skipping amenable, is being evaluated for its potential to restore the mRNA reading ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...